Efficacy and Tolerability of the New Antiepileptic Drugs, II: Treatment of Refractory Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society

Epilepsia

Volumn 45, Issue 5, 2004, Pages 410-423

  French, Jacqueline A ^a,t   Kanner, Andres M ^b   Bautista, Jocelyn ^p   Abou Khalil, Bassel ^d   Browne, Thomas ^e   Harden, Cynthia L ^f   Theodore, William H ^g   Bazil, Carl ^c,h,i   Stern, John ^p   Schachter, Steven C ^p   Bergen, Donna ^b   Hirtz, Deborah ^g   Montouris, Georgia D ^e   Nespeca, Mark ^j   Gidal, Barry ^k   Marks Jr , William J ^l   Turk, William R ^m   Fischer, James H ^n,o   Bourgeois, Blaise ^p   Wilner, Andrew ^p   Faught Jr , R Edward ^q   Sachdeo, Rajesh C ^r   Beydoun, Ahmad ^s   Glauser, Tracy A ^t   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^h Department of Orthopaedic Surgery   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j RADY CHILDREN'S HOSPITAL   (United States)

^k University of Wisconsin Health   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m NEMOURS CHILDREN S CLINIC   (United States)

ⁿ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^o BOSTON CHILDREN S HOSPITAL   (United States)

^p Univ of Alabama School of Medicine ^*

^q UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^s UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^t HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABDOMINAL PAIN; ANOREXIA; ANXIETY DISORDER; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; CHOREOATHETOSIS; CLINICAL TRIAL; COCHRANE LIBRARY; CONFUSION; DEPRESSION; DIPLOPIA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMOTIONAL DISORDER; EPILEPSY; EPILEPTIC STATE; FATIGUE; FECES INCONTINENCE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEADACHE; HUMAN; HYPONATREMIA; INFECTION; INVOLUNTARY MOVEMENT; LENNOX GASTAUT SYNDROME; MEDLINE; META ANALYSIS; MONOTHERAPY; MOTOR DYSFUNCTION; MYOCLONUS; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PARANOIA; PARESTHESIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOSIS; RASH; REVIEW; RHINITIS; SCISEARCH; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; THOUGHT DISORDER; TREMOR; URINE INCONTINENCE; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ACETIC ACIDS; ADOLESCENT; ADULT; AGE FACTORS; AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CLINICAL TRIALS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG APPROVAL; EPILEPSIES, PARTIAL; EPILEPSY, GENERALIZED; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISOXAZOLES; NIPECOTIC ACIDS; PHYSICIAN'S PRACTICE PATTERNS; PIRACETAM; TRIAZINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 2342514201     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2004.06304.x     Document Type: Review

References (84)

1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993;34:453-68.
2. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991;32:429-45.
3. French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 1999;40:803-8 and Neurology 1999;52:1540-5.
4. French J, Smith M, Faught E, et al. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 1999;40:803-8 and Neurology 1999;52:1540-5.
5. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study: the International Gabapentin Study Group. Epilepsia 1994;35:795-801.
6. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-7.
7. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
8. Sivenius J, Kalviainen R, Ylinen A, et al. Double-blind study of Gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-42.
9. Fisher RS, Sachdeo RC, Pellock J, et al. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology 2001;56:743-8.
10. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000;41:479-81.
11. Buetefisch CM, Gutierrez A, Gutmann L. Choreoathetotic movements: a possible side effect of gabapentin. Neurology 1996;46:851-2.
12. Reeves AL, So EL, Sharbrough FW, et al. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-90.
13. Norton JW, Quarles E. Gabapentin-related dyskinesia. J Clin Psychopharmacol 2001;21:623-4.
14. Gil-Nagel A, Gapany S, Blesi K, et al. Incontinence during treatment with gabapentin. Neurology 1997;48:1467-8.
15. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-91.
16. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35:113-21.
17. Schapel GJ, Beran RG, Vajda FJ, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment of resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
18. Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999;40:1767-74.
19. Ben-Menachem E, Henrisksen O, Dam M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
20. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages: Topiramate YD Study Group. Neurology 1996;46:1684-90.
21. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000 mg daily dosages: Topiramate YE Study Group. Neurology 1996;46:1678-83.
22. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
23. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
24. Yen DJ, Yu HY, Guo YC, et al. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000;41:1162-6.
25. Wang Y, Zhou D, Pauli E, et al. Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study. Epilepsy Res 2001;46:271-7.
26. Biton V, Edwards KR, Montouris GD, et al. Ann Pharmacother 2001;35:173-9.
27. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures: a dose-frequency study: the Tiagabine Study Group. Arch Neurol 1997;54:595-601.
28. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
29. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
30. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
31. Barcs G, Walker EG, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-607.
32. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993;15:67-73.
33. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9.
34. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
35. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European Levetiracetam Study Group. Epilepsia 2000;41:1179-86.
36. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000;41:1276-83.
37. Cramer JA, Arrigo C, Van Hammee, et al. Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group. Epilepsia 2000;41:868-74.
38. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9:80-7.
39. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin monotherapy: 1. an 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 88/89. Neurology 1997;49:739-45.
40. Beydoun A, Fischer J, Labar DR, et al. Gabapentin monotherapy, II: a 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures: the US Gabapentin Study Group 82.83. Neurology 1997;49:746-52.
41. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-25.
42. Sachdeo RC, Reife RA, Lim P, et al. Topiramate monotherapy for partial onset seizures. Epilepsia 1997;38:294-300.
43. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999;52:732-7.
44. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000;54:2245-51.
45. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001;57:864-71.
46. Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996;25:191-7.
47. Bhaumik S, Branford D, Duggirala C, et al. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997;6:127-33.
48. Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987;50:682-6.
49. Langan Y, Duncan JS, Sander JW. An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy. Eur Neurol 1999;41:111-3.
50. Thisj RD, Kerr MP. The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication. Seizure 1998;7:379-83.
51. Wong IC, Chadwick DW, Fenwick PB, et al. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999;40:1439-45.
52. Beran RG, Berkovic SF, Dunagan FM, et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 1998;39:1329-33.
53. Boas J, Dam M, Friis ML, et al. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 1996;94:247-52.
54. Marciani MG, Spanedda F, Bassetti MA, et al. Effect of lamotrigine on EEG paroxysmal abnormalities and background activity: a computerized analysis. Br J Clin Pharmacol 1996;42:621-7.
55. Sander JW, Patsalos PN, Oxley JR, et al. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
56. Trenite DG, Rentmeester TW, Scholtes FB, et al. Post-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints. Pharm World Sci 2001;23:1-5.
57. Houtkooper MA, Lammertsma A, Meyer JW, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
58. Biton V, Montouris GD, Ritter F, et al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology 1999;52:1330-7.
59. Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7:207-11.
60. Dooley JM, Camfield PR, Smith E, et al. Topiramate in intractable childhood onset epilepsy: a cautionary note. Can J Neurol Sci 1999;26:271-3.
61. Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 2001;42:1134-40.
62. Abou-Khalil B. Topiramate in the long-term management of refractory epilepsy: Topiramate YOL Study Group. Epilepsia 2000;41:S72-6.
63. Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000;41:338-41.
64. Tartara A, Sartori I, Manni R, et al. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci 1996;17:429-32.
65. Baker GA, Currie NG, Light MJ, et al. The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy: a Canadian study. Seizure 2002;11:6-15.
66. Singh BK, White-Scott S. Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure 2002;11:47-50.
67. Kelly K, Stephen LJ, Sills GJ, Brodie MJ. Topiramate in patients with learning disability and refractory epilepsy. Epilepsia 2002;43:399-402.
68. Kellett MW, Smith DF, Stockton PA, Chadwick DW. Topiramate in clinical practice: first year's postlicensing experience in a specialist epilepsy clinic. J Neurol Neurosurg Psychiatry 1999;66:759-63.
69. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study: Gabapentin Paediatric Study Group. Epilepsia 1999;40:1147-54.
70. Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children: Lamictal Pediatric Partial Seizure Study Group. Neurology 1999;53:1724-31.
71. Elterman RD, Glauser TA, Wyllie E, et al. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999;52:1338-44.
72. Arcas J, Ferrer T, Roche MC, et al. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42:1363-5.
73. Glauser TA, Nigro M, Sachedo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures: the Oxcarbazepine Pediatric Study Group. Neurology 2000;54:2237-44.
74. Glauser TA, Pellock JM, Bebin M, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open trial. Epilepsia 2002;43:518-24.
75. Shimizu T, Yamashita Y, Satoi M, et al. Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997;19:366-8.
76. Sheridan PH, Jacobs MP. The development of antiepileptic drugs for children: report from the NIH workshop, Bethesda, Md, Feb. 17-18, 1994. Epilepsy Res 1996;23:87-92.
77. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996;46:852-3.
78. Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome: Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12.
79. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
80. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox-Gastaut syndrome). Epilepsia 1997;38:68-73.
81. Janszky J, Rasonyi G, Halasz P, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level: report of two cases. Clin Neurophamacol 2000;23:86-9.
82. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999;52:1882-7.
83. Glauser TA, Levisohn PM, Ritter F, et al. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial: Topiramate YL Study Group. Epilepsia 2000;41:S86-90.
84. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313:1169-74.